AU2006230478B2 - Treatment of eye disorders with sirtuin modulators - Google Patents

Treatment of eye disorders with sirtuin modulators Download PDF

Info

Publication number
AU2006230478B2
AU2006230478B2 AU2006230478A AU2006230478A AU2006230478B2 AU 2006230478 B2 AU2006230478 B2 AU 2006230478B2 AU 2006230478 A AU2006230478 A AU 2006230478A AU 2006230478 A AU2006230478 A AU 2006230478A AU 2006230478 B2 AU2006230478 B2 AU 2006230478B2
Authority
AU
Australia
Prior art keywords
compound
formula
further embodiment
attendant definitions
sirtuin activator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006230478A
Other languages
English (en)
Other versions
AU2006230478A1 (en
Inventor
Michelle Dipp
Michael Milburn
Christopher R. Westphal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirtris Pharmaceuticals Inc
Original Assignee
Sirtris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals Inc filed Critical Sirtris Pharmaceuticals Inc
Publication of AU2006230478A1 publication Critical patent/AU2006230478A1/en
Application granted granted Critical
Publication of AU2006230478B2 publication Critical patent/AU2006230478B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
AU2006230478A 2005-03-30 2006-03-30 Treatment of eye disorders with sirtuin modulators Ceased AU2006230478B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US66717905P 2005-03-30 2005-03-30
US60/667,179 2005-03-30
US68425205P 2005-05-25 2005-05-25
US60/684,252 2005-05-25
US11/374,278 US20070014833A1 (en) 2005-03-30 2005-10-28 Treatment of eye disorders with sirtuin modulators
US11/374,278 2005-10-28
PCT/US2006/011930 WO2006105403A2 (en) 2005-03-30 2006-03-30 Treatment of eye disorders with sirtuin modulators

Publications (2)

Publication Number Publication Date
AU2006230478A1 AU2006230478A1 (en) 2006-10-05
AU2006230478B2 true AU2006230478B2 (en) 2011-12-22

Family

ID=37054169

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006230478A Ceased AU2006230478B2 (en) 2005-03-30 2006-03-30 Treatment of eye disorders with sirtuin modulators

Country Status (6)

Country Link
US (1) US20070014833A1 (enExample)
EP (1) EP1863462A2 (enExample)
JP (1) JP2008538215A (enExample)
AU (1) AU2006230478B2 (enExample)
CA (1) CA2603009A1 (enExample)
WO (1) WO2006105403A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090169585A1 (en) * 2003-10-23 2009-07-02 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
AU2005207029B2 (en) * 2004-01-20 2011-09-01 Brigham Young University Novel sirtuin activating compounds and methods for making the same
US7522995B2 (en) * 2004-02-05 2009-04-21 Nortrup Edward H Method and system for providing travel time information
US20050227327A1 (en) * 2004-02-10 2005-10-13 Brenner Charles M Nicotinamide riboside kinase compositions and methods for using the same
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
US7998974B2 (en) 2005-03-03 2011-08-16 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
WO2006127987A2 (en) * 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007041641A1 (en) * 2005-10-03 2007-04-12 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
EP2007366A2 (en) * 2006-03-24 2008-12-31 Charles H. CELLA Animal product enrichment using resveratrol
WO2008060400A2 (en) * 2006-11-15 2008-05-22 Sirtris Pharmaceuticals, Inc. Sirtuin polymorphisms and methods of use thereof
CA2676609A1 (en) * 2007-01-26 2008-07-31 Washington University Methods and compositions for treating neuropathies
EP2687208A1 (en) 2007-09-12 2014-01-22 The Trustees of Columbia University in the City of New York Compositions and Methods for Treating Macular Degeneration
EA021938B1 (ru) 2008-05-01 2015-10-30 Сертрис Фармасьютикалз, Инк. Хинолины и их аналоги в качестве модуляторов сиртуина
KR20110036602A (ko) 2008-07-03 2011-04-07 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 벤즈이미다졸 및 관련 유사체
AU2009295948B2 (en) 2008-09-29 2013-12-05 GlaxoSmithKline, LLC Quinazolinone, quinolone and related analogs as sirtuin modulators
US9556201B2 (en) 2009-10-29 2017-01-31 Glaxosmithkline Llc Bicyclic pyridines and analogs as sirtuin modulators
US20110105990A1 (en) * 2009-11-04 2011-05-05 Silvestrini Thomas A Zonal drug delivery device and method
US9125858B2 (en) 2009-11-30 2015-09-08 Wilmore Labs L.L.C. Compositions and methods relating to resveratrol
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
US8937055B2 (en) 2010-07-15 2015-01-20 Takeda Pharmaceutical Company Limited Heterocyclic ring compound having muscle cell or adipocyte differentiation regulating action
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
CA2833806A1 (en) * 2011-04-28 2012-11-01 Claire Mitchell Method for treatment of macular degeneration by modulating p2y12 or p2x7 receptors
EP3967297A1 (en) 2011-04-29 2022-03-16 Allergan, Inc. Sustained release latanoprost implant
JP5848042B2 (ja) 2011-06-29 2016-01-27 株式会社ロッテ 眼疲労抑制組成物及びそれを含む飲食品
EP3466418A1 (en) 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
JP6170047B2 (ja) 2011-08-31 2017-07-26 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アポトーシス−ターゲティングナノ粒子
US8916528B2 (en) 2011-11-16 2014-12-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
JP6356614B2 (ja) 2012-02-17 2018-07-11 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド 薬剤のミトコンドリア輸送のためのナノ粒子
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
JP5948139B2 (ja) * 2012-05-11 2016-07-06 ヒノキ新薬株式会社 サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤
WO2014059034A2 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
SG11201503774PA (en) 2012-11-13 2015-06-29 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
ES2952032T3 (es) 2013-03-15 2023-10-26 Washington University St Louis Administración de mononucleótido de nicotinamida en el tratamiento de ojo seco
CN105228627B (zh) 2013-03-15 2018-07-13 纽斯尔特科学公司 亮氨酸和烟酸降低脂质水平
MX2016011063A (es) 2014-02-27 2016-11-30 Nusirt Sciences Inc Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica.
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
EP3187179A4 (en) * 2014-08-28 2018-02-07 Keio University Pharmaceutical composition for prophylaxis and/or treatment of corneal and conjunctival diseases or presbyopia containing stilbene compound as active ingredient
JP6520019B2 (ja) * 2014-08-28 2019-05-29 学校法人昭和大学 新規スチルベン誘導体
JP2018100222A (ja) * 2015-04-20 2018-06-28 学校法人慶應義塾 角膜損傷の治療剤、改善剤または予防剤
WO2018052019A1 (ja) * 2016-09-13 2018-03-22 めぐみ 田中 視覚機能改善剤及び視覚機能の改善方法
KR102116303B1 (ko) * 2016-11-14 2020-05-29 밍우 왕 안구 표면 질환 치료를 위한 제형 및 관련 방법
JP6986345B2 (ja) * 2016-11-18 2021-12-22 ロート製薬株式会社 経口組成物及びその製造方法
ES2673942B1 (es) * 2016-11-23 2019-04-09 Consejo Superior Investigacion Compuestos acilados para el tratamiento de patologias oculares
CA3046668A1 (en) * 2017-01-03 2018-07-12 Vitrean, Inc. Methods and devices for treating a retinal detachment
US20200384004A1 (en) * 2017-12-01 2020-12-10 Elysium Health, Inc. Methods and compositions for treating glaucoma
WO2020144753A1 (ja) 2019-01-09 2020-07-16 公立大学法人大阪 神経変性疾患の予防又は治療薬

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087913A2 (en) * 2000-05-12 2001-11-22 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
WO2003103583A2 (en) * 2002-06-10 2003-12-18 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
EP1378247A1 (en) * 2001-04-11 2004-01-07 Senju Pharmaceutical Co., Ltd. Visual function improving agents
WO2005002555A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
WO2006001982A2 (en) * 2004-06-04 2006-01-05 Washington University Methods and compositions for treating neuropathies

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
FR2543550B1 (fr) * 1983-04-01 1985-08-09 Cortial Nouveaux derives de la tetrahydroxy-3', 4',5,7 flavone, leur methode de preparation et leur emploi therapeutique
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
MY106598A (en) * 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
US6028111A (en) * 1996-03-08 2000-02-22 Oxigene, Inc. Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
AU738170B2 (en) * 1996-10-16 2001-09-13 Icn Pharmaceuticals, Inc. Monocyclic L-nucleosides, analogs and uses thereof
GB9712370D0 (en) * 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
DE69841395D1 (de) * 1997-07-31 2010-01-28 Abbott Respiratory Llc Zusammensetzung enthaltend einen HMG-CoA-Reduktasehemmer und eine Nikotinsäureverbindung zur Behandlung von Hyperlipidämie
US7718694B2 (en) * 1997-10-16 2010-05-18 Children's Hospital & Research Center At Oakland Compositions and methods for therapy for diseases characterized by defective chloride transport
US6008260A (en) * 1998-01-09 1999-12-28 Pharmascience Cancer chemopreventative composition and method
US6414037B1 (en) * 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
US6028099A (en) * 1998-03-13 2000-02-22 John Hopkins University, School Of Medicine Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US20030086986A1 (en) * 1998-08-06 2003-05-08 Bruijn Chris De Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
US6096733A (en) * 1998-12-10 2000-08-01 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US6399655B1 (en) * 1998-12-22 2002-06-04 Johns Hopkins University, School Of Medicine Method for the prophylactic treatment of cataracts
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
WO2001041806A1 (en) * 1999-12-07 2001-06-14 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
US7452664B2 (en) * 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
US20020110604A1 (en) * 2000-08-11 2002-08-15 Ashni Naturaceuticals, Inc. Composition exhibiting synergistic antioxidant activity
US7179791B2 (en) * 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
WO2002067988A2 (en) * 2001-02-27 2002-09-06 The Regents Of The University Of Michigan Use of natural egfr inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth receptor
US6716596B2 (en) * 2001-03-12 2004-04-06 The Regents Of The University Of California Agents for replacement of NAD+/NADH system in enzymatic reactions
MXPA04003299A (es) * 2001-10-11 2004-07-23 Alcon Inc Metodos para tratar la resequedad ocular mediante una combinacion de un esteroide antiinflamatorio y un secretagogo muc-1.
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20050080024A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
US20060111318A1 (en) * 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
CA2555675A1 (en) * 2004-02-10 2005-08-25 Trustees Of Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
US20050227327A1 (en) * 2004-02-10 2005-10-13 Brenner Charles M Nicotinamide riboside kinase compositions and methods for using the same
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
EP1765316A2 (en) * 2004-06-16 2007-03-28 The President and Fellows of Harvard College Methods and compositions for modulating bax-ku70-mediated apoptosis
US20060024385A1 (en) * 2004-07-27 2006-02-02 Pedersen Mark A Metabolic capacity enhancing compositions and methods for use in a mammal
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
US20060276416A1 (en) * 2005-01-20 2006-12-07 Sirtris Pharmaceuticals, Inc. Methods and compositions for treating flushing and drug induced weight gain
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
EP1909910A1 (en) * 2005-08-04 2008-04-16 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
US7855289B2 (en) * 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) * 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
DK1957086T3 (en) * 2005-11-18 2018-06-06 Cornell Res Foundation Inc NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE
US20100168084A1 (en) * 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use
EA021424B1 (ru) * 2008-12-19 2015-06-30 Сертрис Фармасьютикалз, Инк. Тиазолопиридиновые соединения, регулирующие сиртуин

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087913A2 (en) * 2000-05-12 2001-11-22 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
EP1378247A1 (en) * 2001-04-11 2004-01-07 Senju Pharmaceutical Co., Ltd. Visual function improving agents
WO2003103583A2 (en) * 2002-06-10 2003-12-18 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
WO2005002555A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
WO2006001982A2 (en) * 2004-06-04 2006-01-05 Washington University Methods and compositions for treating neuropathies

Also Published As

Publication number Publication date
JP2008538215A (ja) 2008-10-16
WO2006105403A2 (en) 2006-10-05
WO2006105403A3 (en) 2007-03-15
CA2603009A1 (en) 2006-10-05
US20070014833A1 (en) 2007-01-18
EP1863462A2 (en) 2007-12-12
AU2006230478A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
US20070014833A1 (en) Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) Treatment of eye disorders with sirtuin modulators
AU2006249816A1 (en) Treatment of eye disorders with sirtuin modulators
Majumdar et al. Potential of the bioflavonoids in the prevention/treatment of ocular disorders
KR102525438B1 (ko) 안과용 활성 약학 성분 전달을 위한 고형 사이클로덱스트린 복합체의 제조
JP5315252B2 (ja) 眼科用薬物の輸送に有用なゲル
Adelli et al. Development of a Δ9-tetrahydrocannabinol amino acid-dicarboxylate prodrug with improved ocular bioavailability
CN1882508B (zh) 水溶性二萜的制备方法及其应用
KR20060127043A (ko) 녹내장성 망막병증 및 시각신경병증의 치료용 약제
CN109152774A (zh) 眼部炎性病症和疾病的组合治疗
JP2021165299A (ja) 薬学的組成物、および１，２，４−オキサジアゾール安息香酸の塩
JP2025087858A (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
Sharma et al. Application of Vitamin E TPGS in ocular therapeutics–Attributes beyond excipient
JP7071269B2 (ja) 対象における虚血再灌流障害のリスクを防ぐか又は減らすための神経保護の性質を有する薬物の使用
EP2271334B1 (en) Methods of treating fibrotic disorders
JP4820170B2 (ja) 虚血性神経障害治療又は予防剤
WO2010056710A1 (en) Compositions and methods for treating eye diseases
JP5087242B2 (ja) ゲル状組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム
US7361681B2 (en) Method of treating amytrophic lateral sclerosis using melatonin
EP4322968B1 (en) Ophthalmic topical composition with ceria nanoparticles for treating diseases of posterior segment of the eye
MXPA04007802A (es) Tratamiento de desordenes oftalmicos utilizando urea o derivados de urea.
KUMAR et al. NANOTECHNOLOGY-DRIVEN THERAPEUTICS: ENHANCING BRAIN DRUG DELIVERY VIA NASAL PATHWAYS
WO2024097327A1 (en) Cannabinoid formulations and use for treatment of emotional disorders and sexual dysfunction
CN118973563A (zh) 5-氨基-2,3-二氢-1,4-酞嗪二酮与富马酸酯的组合
Hippalgaonkar Biopharmaceutical approaches for improved drug delivery across ocular barriers

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired